Post-COVID Syndrome in Bipolar Affective Disorder Patient

Ahmad Firdaus(1*), Adelita Vega Dwiputri(2), Aderisti Irkadiratna(3), Adi Satria Nugraha(4), Adinda Narulitia(5), Era Catur Prasetya(6), Absa Secka(7), Muhammad Muslih(8)

(1) Universitas Muhammadiyah Surabaya, Surabaya, East Java, Indonesia
(2) Universitas Muhammadiyah Surabaya, Surabaya, East Java, Indonesia
(3) Universitas Muhammadiyah Surabaya, Surabaya, East Java, Indonesia
(4) Universitas Muhammadiyah Surabaya, Surabaya, East Java, Indonesia
(5) Universitas Muhammadiyah Surabaya, Surabaya, East Java, Indonesia
(6) Universitas Muhammadiyah Surabaya, Surabaya, East Java, Indonesia
(7) Edward Francis Small Teaching Hospital, Banjul, The Gambia
(8) Taipei Medical University, Taipei, Xinyi, Taiwan
(*) Corresponding Author


Background: Post-COVID is a multifactorial disease that describes the residual effects of acute COVID-19 infection that are continuous or relapsing and in remission. The study found that 87% of people who recovered and were discharged from the hospital showed persistence of at least one symptom even within 60 days. COVID-19 patients who have bipolar disorder require therapeutic adjustments to avoid specific drug interactions between psychotropic drugs and those used in COVID-19 protocols. 

Objective: To determine the treatment of post-COVID patients with bipolar affective disorder.

Methods: Collect and analyze research articles on Update Therapy for Post-COVID Syndrome Patients with Bipolar Affective Disorder. These articles were obtained by searching using Google Scholar, PubMed/NCBI, and SAGE Journal.

Results: The use of combination drugs between antipsychotics and antidepressants with hydroxychloroquine/azithromycin is not recommended because it has side effects that can induce psychiatric symptoms. COVID-19 patients with bipolar disorder (BD) who do not respond to pharmacotherapy may receive electroconvulsive therapy (ECT). Non-pharmacological therapies such as counseling and the use of telepsychiatry are effective in treating mental health and overcoming adverse psychological effects.

Conclusion: COVID-19 patients with bipolar affective disorder require unique therapy to avoid drug interactions and pharma-cotherapy. Non-pharmacological efforts include counseling and telepsychiatry to cope with emotional distress and mental health challenges. However, challenges remain in providing care for these patients.


Post-COVID Syndrome; Long COVID; bipolar affective disorder; therapy

Full Text:



Taribagil P, Creer D, Tahir H. Long COVID syndrome. BMJ Case Rep. 2021;14(4):12–4.

Nabavi N. Long covid: How to define it and how to manage it. BMJ [Internet]. 2020 07 September;m3489. Available from:

Carfì A, Bernabei R, Landi F, Group for the GAC-19 P-ACS. Persistent Symptoms in Patients After Acute COVID-19. JAMA [Internet]. 2020 Aug 11; 324(6): 603–5. Available from:

Athiyyah, Santoso H. Mental Health Problems in the Covid-19 Period. J Ris and Pengabdi Masy [Internet]. 2021; 1(0SE-Articles): 170–85. Available from:

Xue S, Husain MI, Ortiz A, Husain MO, Daskalakis ZJ, Mulsant BH. COVID-19: Implications for bipolar disorder clinical care and research. SAGE OpenMed. 2020; 8: 205031212098117.

Rowland TA, Marwaha S. Epidemiology and risk factors for bipolar disorder. Ther Adv Psychopharmacol [Internet]. 2018 26 September; 8 (9): 251–69. Available from:

Riskesdas 2013. Badan Penelitian dan Pengembangan Kesehatan. Kemendtrian Kesehatan RI. 2013. H.125-129.

Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: An overview. Diabetes Metab Syndr Clin Res Rev [Internet]. 2021 May 30; 15 (3): 869–75. Available from:

Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Auckl) [Internet]. 2021; 53 (10): 737–54. Available from:

Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet [Internet]. 2021 Jan; 397 (10270): 220–32. Available from:

Mazza M, Marano G, Janiri L, Sani G. Managing Bipolar Disorder patients during COVID-19 outbreak. Bipolar Disorder. 2020; 22(8):870–1.

Bobo W V. The Diagnosis and Management of Bipolar I and II Disorders: Clinical Practice Update. Mayo Clin Proc [Internet]. 2017; 92 (10): 1532–51. Available from:

Ceban F, Nogo D, Carvalho IP, Lee Y, Nasri F, Xiong J, et al. Association between Mood Disorders and Risk of COVID-19 Infection, Hospitalization, and Death: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021;1–13.

Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med [Internet]. 2020 Jun 4; 46(6): 1089–98. Available from:

Steardo L, Steardo L, Verkhratsky A. Psychiatric face of COVID-19. Transl Psychiatry [Internet]. 2020; 10(1). Available from:

Shah N, Grover S, Rao Gp. Clinical Practice Guidelines for Management of Bipolar Disorder. Indian J Psychiatry [Internet]. 2017; 59 (5): 51. Available from:

Karrouri R, Hammani Z, Otheman Y. Managing Bipolar Disorder in Time of COVID-19 Pandemic. Med Clin Res Open Access. 2020; 1(1): 20–3.

Kashaninasab F, Dashdebi RP, Ghalehbandi MF. Comorbidity of Coronavirus disease (COVID-19) and the first episode of bipolar disorder and its treatment challenges: A case report. Med J Islamic Republic of Iran. 2020; 2020:34–6.

Spelber D, Strakowski SM. Expert opinion in bipolar disorder: Impact of COVID-19 on outcomes and treatment of bipolar disorder. Press Med Psychiatry [Internet]. 2021; 27–28 (April 2020): 100074. Available from:

Subagyo R, Prasetya EC, Hamida A, Rafida M, Ramzi M, Nugraha MT, et al. Paranoid Schizophrenia: Case Report. Journal of Islamic Medicine. 2022; 6(2): 113–8

Article Metrics

Abstract view : 208 times
PDF - 32 times



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Indexed by




Creative Commons License

MAGNA MEDIKA by APKKM is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.